The NSABP B-47 trial, a randomized phase 3 trial including 3270 women with high-risk and HER2-low BC comparing chemotherapy with or without trastuzumab [13], showed no difference in invasive disease-free survival between the groups. This evidence concerns the gene ERBB2 and breast cancer.